Episodic memory and working memory decline with advancing age. Nevertheless, large-
scale population-based studies document well-preserved memory functioning in some older …

Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show
any effect on disease progression in clinical trials, conceivably because the AD subjects are …

Importance Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as
an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its …

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The
recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the …

Heart disease is the major leading cause of death and disability in the world. Mainly
affecting the elderly population, heart disease and its main outcome, cardiovascular …

Alzheimer's disease begins about two decades before the onset of symptoms or neuron
death, and is believed to be caused by pathogenic amyloid-β aggregates that initiate a …

Objective To examine in a 3-year brain imaging study the effects of higher vs lower
adherence to a Mediterranean-style diet (MeDi) on Alzheimer disease (AD) biomarker …

Objective: A variety of measurements have been individually linked to decline in mild
cognitive impairment (MCI), but the identification of optimal markers for predicting disease …

Alzheimer's disease (AD), including its mild cognitive impairment (MCI) phase that may or
may not progress into the AD, is the most ordinary form of dementia. It is extremely important …

To develop targeted intervention strategies for the treatment of Alzheimer's disease, we first
need to identify early markers of brain changes that occur before the onset of cognitive …